Viridian Therapeutics, Inc. (VRDN) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Viridian Therapeutics conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to John Jordan, Vice President of Investor Relations. Thank you. You may begin. Thank you, Daryl. Good morning, everyone, and welcome to the Verdean conference call to discuss the initial clinical data for VRDN001 in patients with thyroid eye disease. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of today. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and 10-Q and other reports on file with the SEC. I would now like to turn the call over to Jonathan Violin, President and Chief Executive Officer of Viridian. Thanks, John, and good morning, everyone. We're excited to share some remarkable data from our ongoing trial of VRDN001 for the treatment of thyroid eye disease, or TED. The results are, frankly, outstanding, and I'm pleased that we can now share our plans for acceleratin...